Cargando…
Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay
Undetectable minimal residual disease (MRD) in Chronic Lymphocytic Leukemia (CLL) has a favorable prognostic outcome compared with MRD that can be detected. This study investigated a flow cytometric assay (CD160-ROR1FCA) targeting the tumor-specific antigens CD160 and receptor tyrosine kinase-like o...
Autores principales: | Farren, Timothy W., Sadanand, Kaushik S., Agrawal, Samir G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744938/ https://www.ncbi.nlm.nih.gov/pubmed/33344247 http://dx.doi.org/10.3389/fonc.2020.597730 |
Ejemplares similares
-
Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia
por: Farren, T W, et al.
Publicado: (2015) -
Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
por: Del Giudice, Ilaria, et al.
Publicado: (2019) -
Measurable residual disease in chronic lymphocytic leukemia
por: Benintende, Giulia, et al.
Publicado: (2023) -
Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
por: Della Starza, Irene, et al.
Publicado: (2019) -
ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy
por: Rebagay, Guilly, et al.
Publicado: (2012)